Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Liposomal doxorubicin hydrochloride|DRUG: Cyclophosphamide|DRUG: Trastuzumab|DRUG: Free doxorubicin hydrochloride|DRUG: Docetaxel
Sponsor: Cephalon, Inc.